Publicaciones en colaboración con investigadores/as de Universitat de Barcelona (102)

2024

  1. A Pilot Study on Proteomic Predictors of Mortality in Stable COPD

    Cells, Vol. 13, Núm. 16

  2. COPD: systemic proteomic profiles in frequent and infrequent exacerbators

    ERJ Open Research, Vol. 10, Núm. 2

  3. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

    Journal of Thrombosis and Haemostasis, Vol. 22, Núm. 8, pp. 2234-2246

  4. Evidence and choice: The BCLC vision for tailoring clinical decision-making

    Journal of Hepatology

  5. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma

    Annals of Oncology, Vol. 35, Núm. 5, pp. 448-457

  6. Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU

    Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432

  7. The ‘BCLC upon progression’ classification: After repeated validation, it is time to incorporate it in trial design

    Liver International

  8. Time since liver transplant and immunosuppression withdrawal outcomes: Systematic review and individual patient data meta-analysis

    Liver International, Vol. 44, Núm. 1, pp. 250-262

  9. Triple Therapy and Clinical Control in B+ COPD Patients: A Pragmatic, Prospective, Randomized Trial

    Archivos de Bronconeumologia, Vol. 60, Núm. 7, pp. 417-422

2023

  1. A new FGF15/19-mediated gut-to-heart axis controls cardiac hypertrophy

    Journal of Pathology, Vol. 261, Núm. 3, pp. 335-348

  2. Author Correction: Defective HNF4alpha-dependent gene expression as a driver of hepatocellular failure in alcoholic hepatitis (Nature Communications, (2019), 10, 1, (3126), 10.1038/s41467-019-11004-3)

    Nature Communications

  3. Comparative effects of glucagon-like peptide-1 receptors agonists, 4-dipeptidyl peptidase inhibitors, and metformin on metabolic syndrome

    Biomedicine and Pharmacotherapy, Vol. 161

  4. Corrigendum: Role of NAFLD on the health related QoL response to lifestyle in patients with metabolic syndrome: The PREDIMED plus cohort(Front. Endocrinol., (2022), 13, (868795), 10.3389/fendo.2022.868795)

    Frontiers in Endocrinology

  5. Dietary Iron, Anemia Markers, Cognition, and Quality of Life in Older Community-Dwelling Subjects at High Cardiovascular Risk

    Nutrients, Vol. 15, Núm. 20

  6. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  7. Nivolumab Plus Cabozantinib with or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results from Cohort 6 of the CheckMate 040 Trial

    Journal of Clinical Oncology

  8. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV)

    Bone Marrow Transplantation

  9. The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

    ESMO Open, Vol. 8, Núm. 3

  10. The outcome of boosting mitochondrial activity in alcohol-associated liver disease is organ-dependent

    Hepatology (Baltimore, Md.), Vol. 78, Núm. 3, pp. 878-895

2022

  1. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update

    Journal of Hepatology, Vol. 76, Núm. 3, pp. 681-693